Andean Court Upholds Colombia HIV Drug License
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Andean Community Court upheld Colombia's compulsory license for an HIV medicine issued two years ago.
- Colombia was found to have properly justified the public‑interest reasons and set an appropriate expiration date for the license.
- ViiV Healthcare is the manufacturer of the HIV drug subject to the compulsory license.
- Andean Community Court determined that Colombia did not breach regional regulations because the license served a public‑interest purpose.
- Colombia Health Ministry said the government complied with its obligation to determine the license duration.
Why it matters: The ruling lets Colombia keep the HIV drug at lower cost, expanding access for patients while confirming that public‑interest compulsory licensing complies with Andean law, limiting ViiV Healthcare’s monopoly profits.
